Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Weighing Higher Add-On Payments For New Drugs, Including CAR-T

Executive Summary

Change would increase maximum new technology add-on payments from 50% to 65% of costs.

You may also be interested in...



Outcomes-Based Pricing: Can It Facilitate The Study Of Precision Dosing?

Roche's Richard Peck says adoption of outcomes-based pricing in the US could be powerful incentive to study precision dosing, although he also calls on drugmakers to put out scientific examples.

Medicare Payment Relief For CAR-T Limited To Higher Add-On Payments In 2020

US Centers for Medicare and Medicaid Services concludes structural changes to existing payment systems to accommodate the high cost of Novartis’ Kymriah and Gilead’s Yescarta are still “premature.”

Medicare Add-On Payments For CAR-T Should Reflect 80% Of Actual Costs, CMS Told

Biopharma firms and providers argue that CMS's current approach to awarding Medicare new technology add-on payments for CAR-T treatment is not suited to the high-cost therapy and is leading some hospitals to mark up billed charges substantially so they can get as much supplemental reimbursement as possible.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel